Menu
Back to Journals » Patient Preference and Adherence » Volume 7
Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability
Authors Anderson M
Received 16 October 2012
Accepted for publication 21 November 2012
Published 10 January 2013 Volume 2013:7 Pages 27—34
DOI https://doi.org/10.2147/PPA.S39233
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Mark Anderson
Great North Children’s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Abstract: Prolonged seizures and status epilepticus are a common acute neurological presentation in pediatric practice. As a result, there is a need for effective and safe medications that can be delivered to convulsing children to effect rapid seizure termination both in hospital and community settings. The challenges of achieving intravenous access, particularly in young children, mandate alternative routes of administration for these drugs. Over the last ten years, midazolam delivered via the buccal mucosa has been demonstrated to be efficacious, safe, and acceptable to children and their caregivers, and a formulation has recently been licensed for use in Europe. The aim of this article is to review the clinical pharmacology with respect to these issues.
Keywords: pediatrics, neurology, pharmacology, buccal midazolam
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.